[HTML][HTML] Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort
L Albiges, S Foulon, A Bayle, B Gachot, F Pommeret… - Nature Cancer, 2020 - nature.com
Patients with cancer are presumed to be at increased risk of severe COVID-19 outcomes
due to underlying malignancy and treatment-induced immunosuppression. Of the first 178 …
due to underlying malignancy and treatment-induced immunosuppression. Of the first 178 …
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort
L Albiges, S Foulon, A Bayle, B Gachot… - Nature …, 2020 - pubmed.ncbi.nlm.nih.gov
Patients with cancer are presumed to be at increased risk of severe COVID-19 outcomes
due to underlying malignancy and treatment-induced immunosuppression. Of the first 178 …
due to underlying malignancy and treatment-induced immunosuppression. Of the first 178 …
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort.
L Albiges, S Foulon, A Bayle, B Gachot… - Nature Cancer, 2020 - europepmc.org
Patients with cancer are presumed to be at increased risk of severe COVID-19 outcomes
due to underlying malignancy and treatment-induced immunosuppression. Of the first 178 …
due to underlying malignancy and treatment-induced immunosuppression. Of the first 178 …